Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Partners With Biotech Startup In Latest India-U.S. Deal

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases

You may also be interested in...



India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results

MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome

India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results

MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome

India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings

BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)

Related Content

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel